Navigation Links
Diagnostic Tests for Malaria Underused in Zambia

Despite improvements in the ability to diagnose malaria, these diagnostic tests are often underused in Zambia, and patients with negative test results are often prescribed anti-malaria medications, according to a study.

The recent introduction of the effective but expensive artemisinin-based (a type of medication) combination therapy for malaria throughout Africa has led to renewed interest in improving the accuracy of diagnosis. The use of rapid antigen-detection diagnostic tests (RDTs) has been proposed as an approach for reducing overtreatment of malaria. The most widely used method to confirm a diagnosis of malaria is microscopy, according to background information in the article.

Davidson H. Hamer, M.D., of the Boston University School of Public Health, Boston, and colleagues from the Zambian Ministry of Health, the Kenyan Medical Research Institute and University of Oxford, assessed the association between use of microscopy and RDT and the prescription of antimalarials in Zambia. The researchers conducted a survey, carried out between March and May 2006, of 104 government and mission health facilities in four districts in Zambia. At each facility, data were collected during one working day on ill outpatients treated at the facility.

An equipment survey in the four districts revealed that 17 percent of the 104 health facilities had functional microscopy; 63 percent had RDTs. Overall, 73 percent of health facilities had at least 1 type of malaria diagnostics available.

Of the 1,717 patients (of all ages) with fever (suspected malaria), 27.8 percent treated in health facilities with malaria diagnostics were tested and 44.6 percent had positive test results. Of patients with negative blood smear results, 58.4 percent were prescribed an antimalarials, as were 35.5 percent of those with a negative RDT result. Most patients with fever (72.6 percent) did not have any diagnostic procedure performed. Antimalarial s were prescribed to 66 percent of these patients. About half of this group received artemether-lumefantrine (an artemisinin-based combination therapy).

In facilities with artemether-lumefantrine in stock, this antimalarial was prescribed to a large proportion of patients with fever with a positive diagnostic test result, but also to some with a negative diagnostic test result (blood smear, 30.4 percent; RDT, 26.7 percent).

"RDTs have been proposed as a cost-effective approach to reducing overtreatment of malaria; under current practice in Zambia, however, their use will not achieve this goal," the authors write.

"Given the widespread increase of artemisinin-based combination therapy in sub-Saharan Africa for management of uncomplicated malaria, there is a need to limit inappropriate use of these expensive new combinations. The increasing body of evidence that a substantial proportion of febrile patients do not have malaria, especially in low to moderate transmission zones, emphasizes the need to educate health center staff on the rational use of artemisinin-based combination therapy, which will require strengthening the availability of malaria diagnostics and enhancing quality control measures so that health care providers will have confidence in the test results."

"The RDT training program in Zambia needs to be restructured such that trainees are provided with clear instructions about how to respond to a negative test result. Without taking these steps, we may rapidly be confronted with widespread resistance of P falciparum to artemisinin-based combination therapy, and the lifespan of these highly effective new therapies will be reduced," the authors conclude.


'"/>




Related medicine news :

1. Cancer Risk From Exposure To Diagnostic X-Rays
2. Fragile X-Associated Tremor /Ataxia Syndrome Need Guidelines For Diagnostic Tests
3. Schizophrenia Gets A New Diagnostic Tool
4. A New Diagnostic Approach To Pediatric Interstitial Lung Disease
5. Diagnostic Procedure For Tuberculosis Made Easy
6. Apollo Hospitals Short-listed to Provide Diagnostics in the UK
7. Diagnostic Test Launched by Ranbaxy for En Masse Screening of Bird Flu
8. Diagnostic Centre Inaugurated for Air Pollution at SRMC
9. Lab Tests And Diagnostics - Next Wave Of Outsourcing
10. New Diagnostic Tool Uncovered Gene Expression Patterns in Recessive Genetic Disorders
11. eGFR Diagnostic Test -A reliable and understandable measure of kidney impairment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/21/2017)... ... 2017 , ... The Bryant Agency, a Georgia based firm ... in the Dalton region, is working in conjunction with the GreenHouse organization in ... abuse. , The GreenHouse is headquartered in Dalton and provides a refuge for ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... assistance and financial planning services to communities in the greater Birmingham area, is ... provide resources to underprivileged young people in the region. , The Chris Hammond ...
(Date:7/21/2017)... ... , ... Hospital M&A activity slowed in the second quarter of 2017, according ... to 23 in the second quarter, up 15% from the 20 publicly announced acquisitions ... in the year-ago second quarter. Only four of the transactions disclosed a purchase price ...
(Date:7/21/2017)... ... July 21, 2017 , ... The ... grant from the C. R. Bard Foundation, Inc. to support the ... , a service available through the nonprofit home care agency. Using evidence-based methods, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased to announce the ... July 17, 2017, Ms. Vu will join West Dermatology’s large network of medical and ... skin cancer , and more. She graduated from the University of Florida College ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
(Date:7/10/2017)... CARLSBAD, Calif. , July 10, 2017  The ... in Boston, MA at the ... unequaled value and unparalleled access to global decision makers ... to draw 800+ life science leaders during two impactful ... Boston, and provides delegates with additional networking opportunities with ...
(Date:7/5/2017)... JERUSALEM , July 5, 2017 ... www.oramed.com ), a clinical-stage pharmaceutical company ... today that it has received approval from the Israel Securities ... Stock Exchange (TASE). Oramed common stock will commence trading on ... Based on the current market capitalization of the Company, it ...
Breaking Medicine Technology: